Top Markets
#1 MON MON +2,760.08%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +52.36%
#4 eCash eCash +37.30%
#5 Siren Siren +24.28%
#6 Collector Crypt Collector Crypt +23.96%
#7 PinGo PinGo +23.93%
#8 SAFEcoin SAFEcoin +19.72%
#9 Janction Janction +19.66%
#10 Beldex Beldex +15.26%
Coin of the day
MON MON
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rangering i aksjer #13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aksjekurs
$0.30840035
Markedsverdi
$94.37M
Endring (1 dag)
0.00%
Endring (1 år)
-34.60%
Land
FR
Handel Sensorion SA (ALSEN)

Kategori

Healthcare
Inntekter for Sensorion SA (ALSEN)
Inntekter i Dec 2025 TTM: $2.73M
Ifølge de nyeste økonomiske rapportene til Sensorion SA er selskapets nåværende inntekter (TTM) $2.73M. I 2023 hadde selskapet inntekter på $6.30M en økning sammenlignet med inntektene i 2022, som var $5.29M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Sensorion SA fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $2.73M -60.56%
2024 $6.92M 9.91%
2023 $6.30M 19.02%
2022 $5.29M 9.15%
2021 $4.85M 69.26%
2020 $2.86M 3.92%
2019 $2.76M 7.54%
2018 $2.56M 10.42%
2017 $2.32M 12,505.95%
2016 $18.41K -89.23%
2015 $171.03K -38.96%
2014 $280.18K -42.85%
2013 $490.29K 60.42%
2012 $305.63K 1,124,142.32%
2011 $27.19 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $52.05B 1,906,201.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.26B 448,772.67%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.92B 546,366.42%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 332,560.08%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.29B 230,302.17%
NL